{"Symbol": "AGEN", "AssetType": "Common Stock", "Name": "Agenus Inc", "Description": "Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company is headquartered in Lexington, Massachusetts.", "CIK": "1098972", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "HEALTHCARE", "Industry": "BIOTECHNOLOGY", "Address": "3 FORBES ROAD, LEXINGTON, MA, UNITED STATES, 02421-7305", "OfficialSite": "https://www.agenusbio.com", "FiscalYearEnd": "December", "LatestQuarter": "2025-09-30", "MarketCapitalization": "105534000", "EBITDA": "-50279000", "PERatio": "None", "PEGRatio": "0", "BookValue": "-8.35", "DividendPerShare": "None", "DividendYield": "None", "EPS": "-1.57", "RevenuePerShareTTM": "3.977", "ProfitMargin": "-0.329", "OperatingMarginTTM": "-0.161", "ReturnOnAssetsTTM": "-0.167", "ReturnOnEquityTTM": "-12.79", "RevenueTTM": "106829000", "GrossProfitTTM": "87000", "DilutedEPSTTM": "-1.57", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "0.204", "AnalystTargetPrice": "12.33", "AnalystRatingStrongBuy": "0", "AnalystRatingBuy": "2", "AnalystRatingHold": "1", "AnalystRatingSell": "0", "AnalystRatingStrongSell": "0", "TrailingPE": "-", "ForwardPE": "5.04", "PriceToSalesRatioTTM": "0.988", "PriceToBookRatio": "218.61", "EVToRevenue": "1.386", "EVToEBITDA": "4.442", "Beta": "1.61", "52WeekHigh": "7.34", "52WeekLow": "1.38", "50DayMovingAverage": "3.45", "200DayMovingAverage": "4.238", "SharesOutstanding": "36141700", "SharesFloat": "31257100", "PercentInsiders": "7.596", "PercentInstitutions": "27.686", "DividendDate": "None", "ExDividendDate": "None"}